Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis | PLOS ONE
Kaplan-Meier Estimates of Progression-free and Overall Survival,... | Download Scientific Diagram
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
![PDF] Therapy for metastatic colorectal cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8f71e8746365052e23ebf2293b9b25e7d432b2f6/2-Figure1-1.png "PDF] Therapy for metastatic colorectal cancer. | Semantic Scholar")
PDF] Therapy for metastatic colorectal cancer. | Semantic Scholar
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). | Semantic Scholar
Primary tumor location and survival in colorectal cancer: A retrospective cohort study
Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis | Aging
Overall survival with chemotherapy involving bevacizumab in mcrc... | Download Scientific Diagram
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial - Annals of Oncology
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry | BMC Gastroenterology | Full Text
Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis | Scientific Reports
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Frontiers | FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer - ScienceDirect
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | British Journal of Cancer
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer | NEJM
A) Curve for progression-free survival in patients with metastatic... | Download Scientific Diagram
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium | Business Wire
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer | BMC Cancer
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
Cancers | Free Full-Text | Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
